Showing results (701-710 of 826) with videos related to

Sort By:
Pageof 83
Journal of Biochemistry|July 29, 1999
High-level expression of human lactoferrin in milk of transgenic mice using genomic lactoferrin sequenceS J Kim, B H Sohn, S Jeong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2013
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)H R Kim, K H Jung, S-A Im, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 28, 2026
Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's DiseaseHan Kyu Na, Yeeun Sun, Chan Wook Park, et al.
Neurobiology of Aging|February 25, 2021
Different patterns of β-amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonismSeok Jong Chung, Sangwon Lee, Han Soo Yoo, et al.
Journal of Virus Eradication|May 26, 2015
Cervical cytological abnormalities and HPV infection in perinatally HIV-infected adolescentsJ Ananworanich, W Prasitsuebsai, S J Kerr, et al.
Lancet (London, England)|June 18, 2013
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study, M A Boyd, N Kumarasamy, et al.
Frontiers in Medicine|July 3, 2023
Long-term functional and structural outcomes in X-linked retinoschisis: implications for clinical trialsBeau J Fenner, Jonathan F Russell, Arlene V Drack, et al.
Chemical Communications (Cambridge, England)|May 12, 2017
Isolated, well-defined organovanadium(iii) on silica: single-site catalyst for hydrogenation of alkenes and alkynesH Sohn, J Camacho-Bunquin, R R Langeslay, et al.
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 14, 2019
A Longitudinal Study of Behavioral Risk, Adherence, and Virologic Control in Adolescents Living With HIV in AsiaJeremy L Ross, Sirinya Teeraananchai, Pagakrong Lumbiganon, et al.
Pageof 83